Association between high galectin expression and poor prognosis in hematologic cancers: a systematic review and meta-analysis

References

• Van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352(9142):1731–1738. DOI:10.1016/S0140-6736(98)04058-6
   PubMed Web of Science ®Google Scholar
• Raff T, Gökbuget N, Lüschen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007;109(3):910–915. DOI:10.1182/blood-2006-07-037093
   PubMed Web of Science ®Google Scholar
• Ben Lassoued A, Nivaggioni V, Gabert J. Minimal residual disease testing in hematologic malignancies and solid cancer. Expert Rev Mol Diagn 2014;14(6):699–712. DOI:10.1586/14737159.2014.927311
   PubMed Web of Science ®Google Scholar
• O'Brien S, Del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood. 1995;85(2):307–318. DOI:10.1182/blood.V85.2.307.307
   PubMed Web of Science ®Google Scholar
• Noren DP, Long BL, Norel R, et al. A crowdsourcing approach to developing and assessing prediction algorithms for AML prognosis. PLoS Comput Biol. 2016;12(6):e1004890. DOI:10.1371/journal.pcbi.1004890
   PubMed Web of Science ®Google Scholar
• Burkhardt B, Hermiston ML. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol. 2019;185(6):1158–1170. DOI:10.1111/bjh.15793
   PubMed Web of Science ®Google Scholar
• Siegel RLJ, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. DOI:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. DOI:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Toscano MA. Turning ‘sweet’ on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol. 2009;9(5):338–352. DOI:10.1038/nri2536
   PubMed Web of Science ®Google Scholar
• Dong R, Zhang M, Hu QY, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy. Int J Mol Med 2018;41(2):599–614.
   PubMed Web of Science ®Google Scholar
• Kaminker JD, Timoshenko AV. Expression, Regulation, and functions of the galectin-16 gene in human cells and tissues. Biomolecules. 2021;11:12.
   Web of Science ®Google Scholar
• Sciacchitano S, Lavra L, Morgante A, et al. Galectin-3: One molecule for an alphabet of diseases, from A to Z. Int J Mol Sci. 2018;19:2.
   Web of Science ®Google Scholar
• Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5(1):29–41. DOI:10.1038/nrc1527
   PubMed Web of Science ®Google Scholar
• De Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009;11(9):811–817. DOI:10.1093/eurjhf/hfp097
   PubMed Web of Science ®Google Scholar
• Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010;12(8):826–832. DOI:10.1093/eurjhf/hfq091
   PubMed Web of Science ®Google Scholar
• De Boer RA, Van Veldhuisen DJ, Gansevoort RT, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012;272(1):55–64. DOI:10.1111/j.1365-2796.2011.02476.x
   PubMed Web of Science ®Google Scholar
• Chow SL, Maisel AS, Anand I, et al. Role of biomarkers for the prevention, assessment, and management of heart failure. A scientific statement from the American heart association. Circulation. 2017;135(22):E1054–E1E91.
   PubMed Web of Science ®Google Scholar
• O'Seaghdha CM, Hwang SJ, Ho JE, et al. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol. 2013;24(9):1470–1477.
   PubMed Web of Science ®Google Scholar
• Chen SC, Kuo PL. The role of galectin-3 in the kidneys. Int J Mol Sci. 2016;17:4.
   Google Scholar
• Desmedt V, Desmedt S, Delanghe JR, et al. Galectin-3 in renal pathology: more than just an innocent bystander? Am J Nephrol. 2016;43(5):305–317. DOI:10.1159/000446376
   PubMed Web of Science ®Google Scholar
• Plattel WJ, Alsada ZND, Van Imhoff GW, et al. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC. Br J Haematol 2016;175(5):868–875. DOI:10.1111/bjh.14317
   PubMed Web of Science ®Google Scholar
• Welton JL, Khanna S, Giles PJ, et al. Proteomics analysis of bladder cancer exosomes. Mol Cell Proteom. 2010;9(6):1324–1338. DOI:10.1074/mcp.M000063-MCP201
   PubMed Web of Science ®Google Scholar
• Arcolia V, Journe F, Wattier A, et al. Galectin-1 is a diagnostic marker involved in thyroid cancer progression. Int J Oncol 2017;51(3):760–770. DOI:10.3892/ijo.2017.4065
   PubMed Web of Science ®Google Scholar
• Arcolia V, Journe F, Renaud F, et al. Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer. Oncol Lett. 2017;14(4):4183–4189. DOI:10.3892/ol.2017.6719
   PubMed Web of Science ®Google Scholar
• Wang JT, Liu YD, Yang YF, et al. High expression of galectin-7 associates with poor overall survival in patients with non-metastatic clear-cell renal cell carcinoma. Oncotarget. 2106;7(27):41986–41995. DOI:10.18632/oncotarget.9749
   PubMedGoogle Scholar
• Xu YY, Li CF, Sun JH, et al. Antitumor effects of galectin-3 inhibition in human renal carcinoma cells. Exp Biol Med 2016;241:1365–1373. DOI:10.1177/1535370216630839
   Web of Science ®Google Scholar
• Aboulhagag NA, El-Deek HEM, Sherif MF. Expression of galectin-1 and galectin-3 in renal cell carcinoma; immunohistochemical study. Ann Diagn Pathol. 2018;36:31–37. DOI:10.1016/j.anndiagpath.2018.06.005
   PubMed Web of Science ®Google Scholar
• Shen JJ, Person MD, Zhu JJ, et al. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 2004;64(24):9018–9026. DOI:10.1158/0008-5472.CAN-04-3262
   PubMed Web of Science ®Google Scholar
• Kalfert D, Ludvikova M, Kholova I, et al. Combined use of galectin-3 and thyroid peroxidase improves the differential diagnosis of thyroid tumors. Neoplasma. 2020;67(1):164–170. DOI:10.4149/neo_2019_190128N86
   PubMed Web of Science ®Google Scholar
• Cedeno-Laurent F, Watanabe R, Teague JE, et al. Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood. 2012;119(15):3534–3538. DOI:10.1182/blood-2011-12-396457
   PubMed Web of Science ®Google Scholar
• Holst JM, Ludvigsen M, Hamilton-Dutoit SJ, et al. High intratumoural galectin-1 expression predicts adverse outcome in ALK- ALCL and CD30+ PTCL-NOS. Hematol Oncol. 2020;38(1):59–66. DOI:10.1002/hon.2702
   PubMed Web of Science ®Google Scholar
• Kamper P, Ludvigsen M, Bendix K, et al. Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood. 2011;117(24):6638–6649. DOI:10.1182/blood-2010-12-327346
   PubMed Web of Science ®Google Scholar
• Ouyang J, Plutschow A, Von Strandmann EP, et al. Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood. 2013;121(17):3431–3433. DOI:10.1182/blood-2012-12-474569
   PubMed Web of Science ®Google Scholar
• Cheng CL, Hou HA, Lee MC, et al. Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood. 2013;121(16):3172–3180. DOI:10.1182/blood-2012-07-443762
   PubMed Web of Science ®Google Scholar
• Iurisci I, Tinari N, Natoli C, et al. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res. 2000;6(4):1389–1393.
   PubMed Web of Science ®Google Scholar
• Koh YW, Jung SJ, Park CS, et al. LGALS3 as a prognostic factor for classical Hodgkin's lymphoma. Mod Pathol. 2014;27(10):1338–1344. DOI:10.1038/modpathol.2014.38
   PubMed Web of Science ®Google Scholar
• Alame M, Cornillot E, Cacheux V, et al. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling. Theranostics. 2021;11(8):3565–3579. DOI:10.7150/thno.54343
   PubMed Web of Science ®Google Scholar
• Lee BH, Park Y, Kim JH, et al. Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma. Front Oncol. 2021;11: 669817. DOI:10.3389/fonc.2021.669817
   PubMed Web of Science ®Google Scholar
• Nakajima R, Miyagaki T, Kamijo H, et al. Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma. J Dermatol Sci 2019;96(3):134–142. DOI:10.1016/j.jdermsci.2019.09.004
   PubMed Web of Science ®Google Scholar
• El Leithy AA, Helwa R, Assem MM, et al. Expression profiling of cancer-related galectins in acute myeloid leukemia. Tumor Biol. 2015;36(10):7929–7939. DOI:10.1007/s13277-015-3513-0
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J. 2009;339:b2535. DOI:10.1136/bmj.b2535
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology – a proposal for reporting. J Am Med Assoc. 2000;283(15):2008–2012.
   PubMed Web of Science ®Google Scholar
• Asayama T, Tamura H, Ishibashi M, et al. Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes. Oncotarget. 2017;8(51):88904–88917. DOI:10.18632/oncotarget.21492
   PubMedGoogle Scholar
• Gao N, Wang XX, Sun JR, et al. Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens. Ann Hematol 2017;96(5):711–718. DOI:10.1007/s00277-017-2948-3
   PubMed Web of Science ®Google Scholar
• Gao N, Yu WZ, Guo NJ, et al. Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system. Leuk Lymphoma. 2017;58(6):1394–1402. DOI:10.1080/10428194.2016.1243677
   PubMed Web of Science ®Google Scholar
• Ruvolo PP, Hu CW, Qiu YH, et al. LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. Ebiomedicine. 2019;44:126–137. DOI:10.1016/j.ebiom.2019.05.025
   PubMed Web of Science ®Google Scholar
• Wang JY, Gao N, Wang XX, et al. Prognostic Factors in Acute Myeloid Leukemia with t(8;21)/AML1-ETO: Strategies to Define High-Risk Patients. Ind J Hematol Blood Trans. 2022;38(4):631–637. DOI:10.1007/s12288-021-01507-9
   PubMed Web of Science ®Google Scholar
• Wdowiak K, Gallego-Colon E, Francuz T, et al. Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. Oncol Lett. 2019;17(1):1019–1029.
   PubMed Web of Science ®Google Scholar
• The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10352):563-591.
   PubMed Web of Science ®Google Scholar
• Steele M, Narendran A. Mechanisms of defective erythropoiesis and anemia in pediatric acute lymphoblastic leukemia (ALL). Ann Hematol. 2012;91(10):1513–1518. DOI:10.1007/s00277-012-1475-5
   PubMed Web of Science ®Google Scholar
• Chennamadhavuni A, Lyengar V, Mukkamalla SKR, et al. Leukemia. StatPearls. Treasure Island (FL); StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC. 2022.
   Google Scholar
• Heilmeier B, Spiekermann K, Bohlander S, et al. Current methods for diagnosing leukemia in adults. Deutsch Med Wochenschr. 2009;134(23):1222–1226. DOI:10.1055/s-0029-1222598
   PubMed Web of Science ®Google Scholar
• Zhang YP, Xue S, Hao Q, et al. Galectin-9 and PSMB8 overexpression predict unfavorable prognosis in patients with AML. J Cancer. 2021;12(14):4257–4263. DOI:10.7150/jca.53686
   PubMed Web of Science ®Google Scholar
• Dama P, Tang M, Fulton N, et al. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019;7(1):175. DOI:10.1186/s40425-019-0611-3
   PubMedGoogle Scholar
• Kikushige Y, Miyamoto T, Yuda J, et al. A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015;17(3):341–352. DOI:10.1016/j.stem.2015.07.011
   PubMed Web of Science ®Google Scholar
• Pang NN, Alimu X, Chen R, et al. Activated Galectin-9/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia. FASEB J. 2021;35:7.
   Web of Science ®Google Scholar
• Nasri F, Sadeghi F, Behranvand N, et al. Oridonin could inhibit inflammation and T-cell immunoglobulin and Mucin-3/Galectin-9 (TIM-3/Gal-9) autocrine loop in the acute myeloid leukemia cell line (U937) as compared to doxorubicin. Iran J Allergy Asthma Immunol. 2020;19(6):602–611.
   PubMed Web of Science ®Google Scholar
• Yang RY, Sun LL, Li CF, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021;12:1.
   PubMed Web of Science ®Google Scholar
• Banh A, Zhang J, Cao H, et al. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res. 2011;71(13):4423–4431. DOI:10.1158/0008-5472.CAN-10-4157
   PubMed Web of Science ®Google Scholar
• Salazar F, Sewell HF, Shakib F, et al. The role of lectins in allergic sensitization and allergic disease. J Allergy Clin Immunol. 2013;132(1):27–36. DOI:10.1016/j.jaci.2013.02.001
   PubMed Web of Science ®Google Scholar
• Yi L, Feng Y, Chen D, et al. Association between galectin-13 expression and eosinophilic airway inflammation in chronic obstructive pulmonary disease. Copd. 2023;20(1):101–108. DOI:10.1080/15412555.2022.2162377
   PubMedGoogle Scholar
• Rotshenker S. Galectin-3 (MAC-2) controls phagocytosis and macropinocytosis through intracellular and extracellular mechanisms. Front Cell Neurosci. 2022;16:949079. DOI:10.3389/fncel.2022.949079
   PubMed Web of Science ®Google Scholar
• Sewgobind NV, Albers S, Pieters RJ. Functions and inhibition of galectin-7, an emerging target in cellular pathophysiology. Biomolecules. 2021;11:11.
   Web of Science ®Google Scholar
• Mathew MP, Donaldson JG, Hanover JA. Evaluating the role of galectins in clathrin-independent endocytosis. Methods Mol Biol. 2022;2442:391–411. DOI:10.1007/978-1-0716-2055-7_21
   PubMedGoogle Scholar
• Fei F, Zhang M, Tarighat SS, et al. Galectin-1 and galectin-3 in B-cell precursor acute lymphoblastic leukemia. Int J Mol Sci. 2022;23:22.
   Web of Science ®Google Scholar